Investing: Daraxonrasib Shows 90.2% Disease Control in Pancreatic Cancer Trial

  • Targeted Inhibition: The drug blocks mutant RAS proteins, which act like jammed cellular switches driving unchecked cancer growth.
  • Combination Therapy: Daraxonrasib is administered alongside standard chemotherapeutic agents like gemcitabine and nab-paclitaxel to enhance tumor response.
  • Monitoring Disease Progression: While early imaging shows significant tumor shrinkage and prolonged disease control, clinicians emphasize that microscopic cancer cells may still persist.

Pancreatic ductal adenocarcinoma remains one of the most treatment-resistant malignancies in oncology, characterized by limited therapeutic options and poor survival outcomes in metastatic stages.

With a median follow-up of 18.3 months, the therapeutic regimen yielded a disease control rate of 90.2 percent and a median duration of response of 11.1 months, according to Investing. The drug works by disrupting RAS mutations, which drive cellular proliferation across the majority of pancreatic cancer cases as well as select lung and ovarian tumors, alarabiya.net reported.

Trial investigators observed that approximately 8 percent of participants experienced complete radiological disappearance of visible tumors on computed tomography scans, though medical experts cautioned that non-visible malignant cells may remain.

Daraxonrasib gives pancreatic cancer patients hope

Clinical evaluations indicate the agent can extend median overall survival compared to secondary rounds of chemotherapy, according to Vietnam.vn. Pascal Hammel, an oncologist coordinating the clinical trial in France, emphasized that early drug availability remains critical for managing aggressive disease progressions, Vietnam.vn reported.

Metric Trial Outcome
Patient Cohort Size 61 participants
Disease Control Rate 90.2 percent
Median Duration of Response 11.1 months
Median Follow-up 18.3 months

EMA Approves Daraxonrasib in Rapid Review

The European Medicines Agency granted a rapid review and approval for daraxonrasib as a broad-spectrum RAS-targeted therapy for pancreatic cancer, completing its scientific evaluation in just over 100 days alongside the U.S. Food and Drug Administration, Vietnam.vn reported. Revolution Medicines, the U.S. pharmaceutical developer behind the compound, reported nearly 198 million dollars in net product revenues during its initial partial quarter of U.S. sales, Investing reported.

Daraxonrasib Delivers Breakthrough Survival Gains in Pancreatic Cancer

Following the clinical data release, analyst Robert Burns from H.C. Wainwright raised his price target for Revolution Medicines stock to 350 dollars from 280 dollars while maintaining a buy rating, noting growing confidence in commercial execution and pipeline potential, Investing reported.

Elena Garalda, chairing the specialized European cancer research symposium where the findings were discussed, said that combining the drug with chemotherapy may improve overall survival opportunities and delay tumor progression, alarabiya.net reported.

Despite regulatory green lights in the European Union, regional access remains contingent on domestic health technology assessments, such as documentation reviews by France’s High Authority for Health prior to pricing negotiations, Vietnam.vn reported. Sam Godfrey from Cancer Research UK characterized the findings as a major leap forward in addressing a molecular target long considered undruggable, alarabiya.net reported.

Investing: Daraxonrasib Shows 90.2% Disease Control in Pancreatic Cancer Trial
Photo: Vietnam.vn

Researchers Stress Need for Larger Long-Term Studies

While the initial data demonstrate deep and durable tumor responses, researchers stress that extended longitudinal studies involving larger patient populations are required to confirm long-term survival benefits.

Wongkee Park from the Memorial Sloan Kettering Cancer Center in the United States said that the trial demonstrated deeper responses and nearly doubled disease control durations, paving the way for future survival extensions, alarabiya.net reported. Investigators continue to evaluate whether these targeted mechanisms can be successfully translated to treat other RAS-mutated solid tumors, including non-small cell lung cancer and ovarian malignancies.

“The results showed an increase in tumor response rates, deeper responses, and a disease control duration approaching double, which may translate into extended patient lifespans in the future,” said Wongkee Park, medical oncologist at Memorial Sloan Kettering Cancer Center, told alarabiya.net.

Daraxonrasib First RAS Pill Nearly Doubles Pancreatic Cancer Survival

References

  • EORTC-NCI-AACR Symposium Clinical Data Presentations on RAS Inhibition, Barcelona.
  • European Medicines Agency (EMA) Scientific Assessment and Regulatory Approvals for Pancreatic Oncology.
  • Cancer Research UK Clinical Trial Reports on Advanced Pancreatic Malignancies and RAS Mutations.
Photo of author

Health Desk

Health Desk at Archyde.

Trump Says US Firms Will Be Banned From Building AI Data Centres Abroad, Threatens ‘Tremendous Tax’ Penalty

Swiss Winemakers Lean on Festive Events, Unfiltered Wine to Counter Sales Drop